Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by AVACTA GROUP PLC
< Previous
1
2
Next >
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
March 26, 2025
From
AVACTA GROUP PLC
Via
GlobeNewswire
Tickers
LSE
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
March 10, 2025
From
AVACTA GROUP PLC
Via
GlobeNewswire
Tickers
LSE
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
March 07, 2025
From
AVACTA GROUP PLC
Via
GlobeNewswire
Tickers
LSE
Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update
March 07, 2025
From
AVACTA GROUP PLC
Via
GlobeNewswire
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
January 16, 2025
From
AVACTA GROUP PLC
Via
GlobeNewswire
Avacta Appoints Brian Hahn as Chief Financial Officer
January 13, 2025
From
AVACTA GROUP PLC
Via
GlobeNewswire
Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
June 21, 2023
From
Avacta Group plc
Via
Business Wire
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
April 27, 2023
From
Avacta Group plc
Via
Business Wire
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
April 06, 2023
From
Avacta Group plc
Via
Business Wire
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
April 05, 2023
From
Avacta Group plc
Via
Business Wire
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
March 28, 2023
From
Avacta Group plc
Via
Business Wire
Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting
March 27, 2023
From
Avacta Group plc
Via
Business Wire
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
January 17, 2023
From
Avacta Group plc
Via
Business Wire
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration
September 05, 2022
From
Avacta Group plc
Via
Business Wire
Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort
September 01, 2022
From
Avacta Group plc
Via
Business Wire
LG Chem Renews License Triggering Payment to Avacta
June 30, 2022
From
Avacta Group plc
Via
Business Wire
AffyXell Expands its Strategic Partnership With GenScript ProBio
May 16, 2022
From
Avacta Group plc
Via
Business Wire
Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake
April 13, 2022
From
Avacta Group plc
Via
Business Wire
Avacta Appoints Dr Christina Coughlin as Non-Executive Director
March 21, 2022
From
Avacta Group plc
Via
Business Wire
Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin
February 03, 2022
From
Avacta Group plc
Via
Business Wire
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
January 18, 2022
From
Avacta Group plc
Via
Business Wire
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
December 22, 2021
From
Avacta Group plc
Via
Business Wire
Avacta Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant
December 15, 2021
From
Avacta Group plc
Via
Business Wire
Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
November 29, 2021
From
Avacta Group plc
Via
Business Wire
Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership
September 29, 2021
From
Avacta Group plc
Via
Business Wire
Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial
August 11, 2021
From
Avacta Group plc
Via
Business Wire
Avacta’s Diagnostic Division Achieves ISO 13485 Certification
July 14, 2021
From
Avacta Group plc
Via
Business Wire
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant
June 29, 2021
From
Avacta Group plc
Via
Business Wire
Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Distribution Agreement
June 21, 2021
From
Avacta Group plc
Via
Business Wire
Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU
June 11, 2021
From
Avacta Group plc
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today